44 related articles for article (PubMed ID: 12209723)
1. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors.
How JA; Legarreta AF; Handley KF; Fellman B; Foster KI; Glassman D; Vuttaradhi VK; Brodsky AL; Lawson B; Frumovitz M; Westin SN; Ramondetta LM; Gershenson DM; Sood AK; Hillman RT
Am J Obstet Gynecol; 2024 May; 230(5):544.e1-544.e13. PubMed ID: 38191019
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors of patients with recurrent uterine malignancies undergoing secondary cytoreductive surgery.
Fang C; Zhang Y; Zhang P; Zhu T
BMC Womens Health; 2024 Jan; 24(1):9. PubMed ID: 38166810
[TBL] [Abstract][Full Text] [Related]
3. Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Grisham RN; Slomovitz BM; Andrews N; Banerjee S; Brown J; Carey MS; Chui H; Coleman RL; Fader AN; Gaillard S; Gourley C; Sood AK; Monk BJ; Moore KN; Ray-Coquard I; Shih IM; Westin SN; Wong KK; Gershenson DM
Int J Gynecol Cancer; 2023 Sep; 33(9):1331-1344. PubMed ID: 37591609
[TBL] [Abstract][Full Text] [Related]
4. Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers.
Di Lorenzo P; Conteduca V; Scarpi E; Adorni M; Multinu F; Garbi A; Betella I; Grassi T; Bianchi T; Di Martino G; Amadori A; Maniglio P; Strada I; Carinelli S; Jaconi M; Aletti G; Zanagnolo V; Maggioni A; Savelli L; De Giorgi U; Landoni F; Colombo N; Fruscio R
Front Oncol; 2022; 12():970918. PubMed ID: 36237308
[TBL] [Abstract][Full Text] [Related]
5. USP9X promotes apoptosis in cholangiocarcinoma by modulation expression of KIF1Bβ via deubiquitinating EGLN3.
Chen W; Song J; Liu S; Tang B; Shen L; Zhu J; Fang S; Wu F; Zheng L; Qiu R; Chen C; Gao Y; Tu J; Zhao Z; Ji J
J Biomed Sci; 2021 Jun; 28(1):44. PubMed ID: 34112167
[TBL] [Abstract][Full Text] [Related]
6. Pressurized intra-peritoneal aerosol chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution patterns but leads to deeper penetration depth of doxorubicin in a sheep model.
Mimouni M; Richard C; Adenot P; Letheule M; Tarrade A; Sandra O; Dahirel M; Lilin T; Lecuelle B; Gélin V; Cohen J; Fauconnier A; Vialard F; Huchon C; Chavatte-Palmer P
BMC Cancer; 2021 Apr; 21(1):461. PubMed ID: 33902518
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research.
Gadducci A; Cosio S
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456205
[TBL] [Abstract][Full Text] [Related]
8. Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian Population.
Bhat RA; Chia YN; Lim YK; Yam KL; Lim C; Teo M
Oman Med J; 2015 Sep; 30(5):344-52. PubMed ID: 26421115
[TBL] [Abstract][Full Text] [Related]
9. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.
Crane EK; Sun CC; Ramirez PT; Schmeler KM; Malpica A; Gershenson DM
Gynecol Oncol; 2015 Jan; 136(1):25-9. PubMed ID: 25448453
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of long-term survivors of recurrent epithelial ovarian cancer.
Iwase H; Takada T; Iitsuka C; Nomura H; Abe A; Taniguchi T; Sakamoto K; Takizawa K; Takeshima N
Int J Clin Oncol; 2015 Feb; 20(1):143-9. PubMed ID: 24664306
[TBL] [Abstract][Full Text] [Related]
11. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms.
Parson EN; Lentz S; Russell G; Shen P; Levine EA; Stewart JH
Am J Surg; 2011 Oct; 202(4):481-6. PubMed ID: 21474115
[TBL] [Abstract][Full Text] [Related]
12. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
Nakayama N; Nakayama K; Yeasmin S; Ishibashi M; Katagiri A; Iida K; Fukumoto M; Miyazaki K
Br J Cancer; 2008 Dec; 99(12):2020-8. PubMed ID: 19018267
[TBL] [Abstract][Full Text] [Related]
13. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.
Bristow RE; Duska LR; Montz FJ
Gynecol Oncol; 2001 Apr; 81(1):92-9. PubMed ID: 11277657
[TBL] [Abstract][Full Text] [Related]
14. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
15. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
[TBL] [Abstract][Full Text] [Related]
16. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.
Munkarah AR; Coleman RL
Gynecol Oncol; 2004 Nov; 95(2):273-80. PubMed ID: 15491746
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.
Bristow RE; Puri I; Chi DS
Gynecol Oncol; 2009 Jan; 112(1):265-74. PubMed ID: 18937969
[TBL] [Abstract][Full Text] [Related]
18. Recurrent micropapillary serous ovarian carcinoma.
Bristow RE; Gossett DR; Shook DR; Zahurak ML; Tomacruz RS; Armstrong DK; Montz FJ
Cancer; 2002 Aug; 95(4):791-800. PubMed ID: 12209723
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
